The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.56 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -3.36 — no flag raisedOK
- Earnings quality 92/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Zhengye Biotechnology Holding Ltd reports it. History and quarterly detail are in the app.
- Swine Vaccines$90.1M
- Distribution Network$61.5M
- Direct Sales Channel$51.9M
- Other Vaccines$13.7M
- Poultry Vaccines$12.5M
Latest filings
- 6-K · Company announcement (foreign filer)2026-06-04
- 20-F · Annual report (foreign filer)2026-04-28
- 6-K · Company announcement (foreign filer)2026-03-25
- 6-K · Company announcement (foreign filer)2026-03-02
- 6-K · Company announcement (foreign filer)2026-02-23
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Zhengye Biotechnology Holding Ltd, every answer cited🔒
- The Intelligence Brief — added when Zhengye Biotechnology Holding Ltd's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.